Apogee Therapeutics is a clinical-stage biotechnology company focused on developing advanced biologic antibody treatments targeting immunological and inflammatory conditions. Its leading pipeline candidate is zumilokibart (formerly known as APG777), a novel half-life-extended monoclonal antibody designed to inhibit IL-13 for conditions like atopic dermatitis, asthma, and eosinophilic esophagitis. Additionally, the company is advancing combination therapy candidates such as APG279 and APG273 to address broader inflammatory and respiratory pathways.